跳至主要内容
临床试验/NL-OMON50212
NL-OMON50212已完成不适用

Efficacy of [18F]-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography (FDG-PET) in Evaluation of Cytological indeterminate Thyroid nodules prior to Surgery: a multicentre cost-effectiveness study. - EfFECTS

Radiologie & Nucleaire Geneeskunde0 个研究点目标入组 132 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
132

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Summary of main criteria from protocol v2.0 paragraph 4.2:
  • In order to be eligible for participation, a subject must meet ALL of the
  • following criteria:
  • 1. solitary thyroid nodule or dominant thyroid nodulus within multinodular
  • disease, cytologically indeterminate (Bethesda category III or IV)
  • 2. Scheduled for surgical excision (preferably) within 2 months of the
  • inclusion date;
  • 3. Age * 18 years;
  • 4. Euthyroid state with a serum TSH or a free T4 level within the institutional
  • upper and lower limits of normal, measured within 2 months of registration. In
  • case of a suppressed TSH: a negative 123I, 131I or 99mTcO4- scintigraphy must
  • be available (*cold nodule*);
  • 5. In patients with multi-nodular disease and a dominant nodule, the nuclear
  • medicine physician responsible for FDG-PET/CT scan interpretation must
  • determine whether the nodule is likely to be discriminated on FDG-PET/CT
  • imaging prior to enrolment;
  • 6. Willing to participate in all aspects of the study;

排除标准

  • Summary of main criteria from protocol v2.0 paragraph 4.3:
  • A subject who meets ANY of the following criteria will be excluded from
  • participation:
  • 1. high prior probability of malignancy (e.g. proven malignant cytology:
  • Bethesda cat. V or VI, malignant lymphadenopathy, PET positive thyroid
  • incidentaloma, genetic predisposition of thyroid carcinoma, prior radiotherapy
  • to the neck, etc.)
  • 2. proven benign disease or insufficient material for diagnosis (Bethesda cat.
  • 3. performance of additional non-routine diagnostic tests affecting patient
  • management (e.g. mutation analysis on cytology)
  • 4. inability to undergo randomisation (i.e. scheduled thyroid resection for
  • other than diagnostic purposes)
  • 5. inability to undergo treatment (i.e. inoperable patients)
  • 6. Contra-indications for FDG-PET/CT (e.g. recent neck infection, poorly
  • regulated diabetes mellitus, pregnant, lactating, severely claustrophobic, etc.)
  • 7. General (inability of informed consent, severe psychiatric disorder)

研究者

发起方
Radiologie & Nucleaire Geneeskunde

相似试验